Key facts
- This page summarizes Joel David Mayersohn's Form 4 filing for CITIUS ONCOLOGY, INC. (CTOR).
- 1 reported transaction and 2 derivative rows are listed below.
- Accepted by SEC: 13 Nov 2026, 16:31.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
No transaction description listed
Additional SEC filing notes
Footnote F1
Includes restricted stock units granted on September 19, 2025, in the amount of 300,000 shares. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Footnote F2
These options were granted on November 12, 2026. The options vest in full on November 12, 2027, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Footnote F3
These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.